高鴻股份(000851.SZ)終止公開發行公司債券
格隆匯12月25日丨高鴻股份(000851.SZ)公佈,公司於2019年12月25日召開了第八屆董事會第三十八次會議,審議通過了《關於終止公開發行公司債券的議案》,同意終止公開發行公司債券。根據公司股東大會對董事會的授權,終止公開發行公司債券事項無需提交股東大會審議。
2019年07月02日,經中國證監會[2019]1188號文核准,公司獲准面向合格投資者公開發行不超過人民幣5億元的公司債券。
自公司啟動公司債發行工作後,公司董事會、管理層與中介機構等一直積極推進相關工作。公司在綜合評估宏觀政策、市場環境、融資成本和融資期限等因素的影響後,決定終止上述發行事宜。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.